(Q48355390)

English

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.

scientific article published on 12 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

phase III clinical trial

0 references

Adaptive radiation therapy

0 references

quality of life

1 reference

based on heuristic

inferred from title

zoledronic acid

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Gillian Duchesne

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

David R. H. Christie

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

14

object named as

Brett Delahunt

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Chantelle Wilcox

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

David Joseph

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Nigel A Spry

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

David S Lamb

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Keen-Hun Tai

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

John Matthews

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Chris Atkinson

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sandra Turner

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Nirdosh Kumar Gogna

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Patrick McElduff

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

12 November 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1260-1270

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Duration of androgen suppression in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of fracture after androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The anti-tumour activity of bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dosimetric intercomparison for multicenter clinical trials using a patient-based anatomic pelvic phantom.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Detailed review and analysis of complex radiotherapy clinical trial planning data: evaluation and initial experience with the SWAN software system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life and satisfaction with outcome among prostate-cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent androgen suppression in prostate cancer: testosterone levels and its implication.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970423-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70423-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23151431%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48355390&oldid=1561961659"